Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 120% above its 3-year average of 45.45%, near the high end of its 3-year range (-544.00%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 164.19% above its 12-month average of -155.79%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
-155.79%
GROSS MARGIN AVG 3Y
45.45%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+164.19%
CURRENT VS 3Y AVG
+120.00%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+142.69%
vs the sector median at left
ProKidney Corp.
Market Cap
$538.01M
Gross Margin
100.00%
TTM Avg
-155.79%
3Y Avg
45.45%
5Y Avg
0.00%
Market Cap
$533.04M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$531.98M
Gross Margin
87.05%
TTM Avg
84.77%
3Y Avg
78.39%
5Y Avg
75.97%
Market Cap
$531.52M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$529.58M
Gross Margin
-195.10%
TTM Avg
-90.32%
3Y Avg
-3207.95%
5Y Avg
-2168.95%
Market Cap
$548.51M
Gross Margin
82.92%
TTM Avg
86.33%
3Y Avg
62.04%
5Y Avg
41.36%
Market Cap
$524.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$519.25M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
31.77%
Market Cap
$557.32M
Gross Margin
98.63%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProKidney Corp. (PROK) | $538.01M | 100.00% | -155.79% | 45.45% | 0.00% |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 87.05% | 84.77% | 78.39% | 75.97% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | -195.10% | -90.32% | -3207.95% | -2168.95% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | 82.92% | 86.33% | 62.04% | 41.36% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | 0.00% | 0.00% | 0.00% | 0.00% |
| Altimmune, Inc. (ALT)vs › | $519.25M | 100.00% | 100.00% | 100.00% | 31.77% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | 98.63% | 100.00% | 100.00% | 100.00% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | 73.28% | 79.19% | 65.08% | 51.90% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -534.96% |
| 2025-12-31 | -544.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
